前列地尔联合丹参川芎嗪治疗高龄不稳定型心绞痛患者的临床观察

发布时间：2018-05-04 23:33

本文选题：前列地尔 + 丹参川芎嗪　；参考：《中国药房》2017年26期

【摘要】：目的:观察前列地尔联合丹参川芎嗪治疗高龄不稳定型心绞痛患者的临床疗效及安全性。方法:选取2011年10月-2015年3月我院收治的不稳定性心绞痛患者150例,按照随机数字表法分为前列地尔组、丹参川芎嗪组、联合组,各50例。3组患者均给予常规治疗,前列地尔组在常规治疗基础上加用前列地尔注射液100μg加入0.9%氯化钠注射液250 mL中,ivgtt,qd;丹参川芎嗪组在常规治疗基础上加用丹参川芎嗪注射液10 mL加入0.9%氯化钠注射液250 mL中,ivgtt,qd;联合组在常规治疗基础上给予等剂量前列地尔注射液和丹参川芎嗪注射液。观察两组患者治疗前后血液流变学指标(全血高切黏度、全血低切黏度、血浆黏度、红细胞比容、纤维蛋白原)、心功能指标[左心室射血分数(LVEF)、每搏输出量(SV)、左室舒张末期内径、舒张期室间隔厚度]、血清C反应蛋白(CRP)、一氧化氮(NO)、内皮素(ET)、超氧化物歧化酶(SOD)水平及临床疗效,并比较不良反应发生情况。结果:治疗前,两组患者血液流变学指标、心功能指标、CRP、NO、ET、SOD水平比较,差异均无统计学意义(P0.05);治疗后,3组患者血浆黏度、全血高切和低切黏度、红细胞比容、纤维蛋白原、血清CRP、ET水平明显降低,LVEF、SV、血清NO、SOD水平明显升高,且联合组上述指标显著优于前列地尔组和丹参川芎嗪组,差异均有统计学意义(P0.05),前列地尔组和丹参川芎嗪组上述指标比较,差异均无统计学意义(P0.05)。联合组患者临床总有效率为90.00%,显著高于前列地尔组的74.00%和丹参川芎嗪组的72.00%,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:前列地尔联合丹参川芎嗪可有效降低不稳定型心绞痛患者的血液黏度,提高心功能,改善内皮功能,减轻心肌缺血缺氧损伤,同时疗效显著,且并未增加药物不良反应,安全性较高。
[Abstract]:Objective: to observe the efficacy and safety of alprostadil combined with salvia miltiorrhiza ligustrazine in the treatment of elderly patients with unstable angina pectoris. Methods: 150 patients with unstable angina pectoris admitted in our hospital from October 2011 to March 2015 were randomly divided into three groups: alprostadil group, salvia miltiorrhiza group, combined group, 50 cases in each group. In the alprostadil group, 100 渭 g alprostadil injection was added into 0.9% sodium chloride 250 mL iv QD on the basis of routine treatment, and in the Danshen ligustrazine group, 10 mL salvia miltiorrhiza injection 10 mL plus 0.9% sodium chloride injection was added on the basis of routine treatment. The combined group was given alprostadil injection and salvia miltiorrhiza injection on the basis of routine therapy. The hemorheological indexes (whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, erythrocyte volume) were observed before and after treatment. Fibrinogen, cardiac function index [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEF), left ventricular end-diastolic diameter, diastolic septal thickness], serum C-reactive protein (CRP), nitric oxide (no), endothelin (et), superoxide dismutase (SOD) and its clinical efficacy. Adverse reactions were compared. Results: before treatment, there was no significant difference between the two groups in the levels of hemorheology, cardiac function and plasma viscosity, high shear and low shear viscosity of whole blood, specific volume of erythrocyte, fibrinogen, and there was no significant difference between the two groups in plasma viscosity, whole blood high shear viscosity, low shear viscosity, erythrocyte volume and fibrinogen. The level of serum CRPN et was significantly lower than that of LVEFV SVL, and the level of no SOD in serum was significantly increased, and the above indexes in the combined group were significantly better than those in the alprostadil group and the salvia miltiorrhiza group (P 0.05), and the above indexes in the alprostadil group and the salvia miltiorrhiza group were higher than those in the control group. The difference was not statistically significant (P 0.05). The total clinical effective rate of the combined group was 90.00g, which was significantly higher than that of the alprostadil group (74.00%) and the salvia miltiorrhiza ligustrazine group (72.00%). The difference was statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: alprostadil combined with Salvia miltiorrhiza Ligustrazine can effectively reduce blood viscosity, improve cardiac function, improve endothelial function and alleviate myocardial ischemia and hypoxia injury in patients with unstable angina pectoris. High safety.
【作者单位】：东方市人民医院内一科;
【分类号】：R541.4

【相似文献】